What isSemaxFDA Status, Evidence and Risks (2026)

What semax is

Semax is a synthetic peptide, seven amino acids long: Met-Glu-His-Phe-Pro-Gly-Pro. It is built on ACTH(4-10), a fragment of ACTH, the hormone that signals the adrenal glands ³.

Two forms exist: semax free base and semax acetate. Neither has a USP or NF monograph (an official US quality standard), and semax has no US Adopted Name ³.

Semax is a registered drug in Russia, sold there as 0.1% and 1% nasal drops ³. That is the only approval FDA's review describes. FDA's review does not list the Russian indications.

Where FDA stands

• Category 2, until Apr 2026. Semax was on FDA's list of compounding substances that "may present significant safety risks." It came off in Apr 2026, one of 12 peptides removed after their nominations were withdrawn ^1,4.
• Removal approved nothing. Semax is not approved by FDA for any use and is not on the 503A bulks list, the list pharmacies need for substances that are not part of an approved drug ². More in Are Peptides Legal?
• FDA staff said no. FDA evaluated both forms on its own after the nominations were withdrawn. Its briefing says the evaluation criteria "weigh against" adding either form to the 503A list ³.
• The panel said yes. On Jul 24, 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 to 5, with 1 abstention, to recommend semax, per one law-firm report ⁵. FDA staff had recommended against all 7 peptides on that agenda ^5,6.
• The vote is advice. FDA decides. Adding semax to the list would take notice-and-comment rulemaking ⁵.
• HHS policy, filed Oct 28, 2026. HHS says it won't take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound semax free base for use in the nose, when the policy's conditions are met ^7,8. It is interim and not binding, and it approves nothing. It lasts while the 503A list goes through rulemaking, and it publishes in the Federal Register Oct 30, 2026 ⁷. Read the full breakdown in HHS's Oct 28 peptide policy.

What the research shows

The evidence is an approval outside the US (Russia) plus small human studies, mostly uncontrolled. FDA's Jul 2026 review lists these ³.

Across all the papers it found, FDA counted roughly 33 to 47 healthy adults, 69 adults with medical conditions and 451 children with depression or tics who had received semax ³. Every human report used the nose. FDA found no literature on semax given by injection ³.

FDA found "insufficient evidence" that semax works for cerebral ischemia, migraine or trigeminal neuralgia, the uses it was nominated for ³. Its review covered only those uses.

Known risks and FDA's concerns

FDA's stated concerns first ^1,3:

• Immune reactions and impurities. No impurity profile, aggregate testing, endotoxin or bioburden data were provided. FDA "cannot rule out the potential for immunogenicity."
• The nasal device. Nobody supplied information on the container, closure or pump. FDA said it "would have strong concerns" about a nasal spray without it, since the device affects dose and quality.
• Bleeding. Animal studies showed anticoagulant and antithrombotic effects. FDA flagged bleeding risk, "particularly in certain populations at risk for bleeding."
• Dopamine. In mice, semax boosted amphetamine-driven dopamine release. FDA called that concerning for abuse potential. No abuse-potential or repeat-dose toxicity studies were found.
• One adverse event report. A consumer reported eye pain and burning after using semax 0.1% nasal drops bought online and was hospitalized. The eye pain had not resolved as of May 2025.

One report cannot show that semax caused the problem. FDA's literature searches also found no published case reports of harm in people, which says little about safety with studies this small ³.

Why it's sold online anyway

Semax is easy to find labeled "research use only" or "not for human consumption." That label is the seller saying the product is not made for people.

Those products skip a prescriber who reviews your health history and any quality check for human use. The one FDA adverse event report on file involved nasal drops bought online ³. Prescription vs Research Peptides covers the difference.

Other peptides on this shelf: DSIP, the one the panel voted down, and dihexa, still awaiting review.

Asked a lot.

The sources.

1. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of Apr 22, 2026). Read it
2. FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of May 14, 2026). Read it
3. FDA. Pharmacy Compounding Advisory Committee briefing document, semax-related bulk drug substances (Jul 2026 meeting). Read it
4. Frier Levitt. FDA Peptides "Do Not Compound" List Update (Apr 16, 2026). Read it
5. Bass Berry. FDA Advisory Committee Recommends Six Peptides for Compounding (Jul 31, 2026). Read it
6. AJMC. FDA Panel Backs 6 Peptides for Compounding (Jul 31, 2026). Read it
7. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Docket HHS-OASH-2026-0496, FR Doc 2026-22192 (filed for public inspection Oct 28, 2026; scheduled to publish in the Federal Register Oct 30, 2026). Read it
8. Hyman, Phelps and McNamara, FDA Law Blog. The PEPTIDE-L Wave Reaches HHS: Enforcement Discretion … Not the Finish Line (Oct 28, 2026). Read it